OST-499 is under clinical development by Oncostellae and currently in Phase I for Uterine Leiomyoma (Uterine Fibroids). According to GlobalData, Phase I drugs for Uterine Leiomyoma (Uterine Fibroids) have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OST-499’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OST-499 overview

OST-499 is under development for the treatment of uterine leiomyoma (uterine fibroids), unspecified gynecological disorders. The drug candidate is a new chemical entity (NCEs). It is administered through oral route. It acts by targeting progesterone receptor (PR). It was under development for the treatment of castration-resistant prostate cancer, colorectal cancer, immune activation and solid tumors.

Oncostellae overview

Oncostellae, is a biotechnology company that focused on development of small molecule drugs for the treatment of cancer. The company is headquartered in Spain.

For a complete picture of OST-499’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.